Minerva Neurosciences, Inc. (NERV) Stock Score, Valuation & Financial Research

Minerva Neurosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NERV

Minerva Neurosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.25. These figures are a research snapshot, not a buy or sell recommendation.

What Minerva Neurosciences, Inc. does

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Minerva Neurosciences is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of proprietary product candidates for the treatment of central nervous system disorders, relying on capital raises and potential future licensing or commercialization agreements to fund operations.

Products and services

  • The company is developing a pipeline of CNS-focused product candidates, including roluperidone (MIN-101) for the treatment of negative symptoms in schizophrenia, seltorexant (MIN-202) for insomnia and depression, and MIN-301 for Parkinson's disease.

Brands and product families

  • Roluperidone — Lead product candidate for the treatment of negative symptoms in schizophrenia. Source
  • Seltorexant — Product candidate for insomnia and depression. Source
  • MIN-301 — Product candidate for Parkinson's disease. Source

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party CROs and CMOs for clinical trial management, data collection, and the manufacturing of drug supplies for clinical studies. Specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various entities developing therapies for schizophrenia, insomnia, depression, and Parkinson's disease, ranging from large established pharmaceutical companies to smaller biotech firms. Source

Business strengths to evaluate

  • Proprietary pipeline of CNS-focused product candidates Source

Business risks and research considerations

  • History of operating losses and uncertainty regarding future profitability Source
  • Dependence on clinical trial success and regulatory approval processes Source
  • Need for additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NERV financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.25
Market capitalization:
151.41M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -394.35M
Free cash flow:
USD -13.51B
Cash:
USD 24.65M
Total debt:
USD 64.96M
EPS:
USD -28.37

What stands out

  • Free cash flow is USD -13.51B, negative for the stored period.
  • The balance sheet shows USD 24.65M of cash versus USD 64.96M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 40.31M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NERV

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NERV fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is NERV's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for NERV to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NERV's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research NERV

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.